For CYP1A1, the frequency of the homozygous *2C variant genotype (GG) was significantly higher in patients (23.1%) than in controls (8%), indicating that individuals carrying this genotype are more likely to increase the risk of developing Ph-ve CML (OR = 4.625, 95% CI = 1.181–18.119, p value = 0.028). Here, CYP1A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.